Open AccessLong-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade
Author(s) -
Allison Betof Warner,
Jessica Palmer,
Alexander N. Shoushtari,
Debra A. Goldman,
Katherine S. Panageas,
Sara A. Hayes,
Raazi Bajwa,
Parisa Momtaz,
Margaret K. Callahan,
Jedd D. Wolchok,
Michael A. Postow,
Paul B. Chapman
Publication year - 2020
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.19.01464
Subject(s) - medicine , discontinuation , ipilimumab , surgery , melanoma , cohort , retrospective cohort study , stage (stratigraphy) , hazard ratio , survival analysis , cancer , confidence interval , immunotherapy , biology , paleontology , cancer research
To analyze long-term outcomes after treatment discontinuation of anti-programmed death-1 (anti-PD-1) therapy in a cohort of patients with melanoma with the longest follow-up yet available to our knowledge, including a majority of patients treated outside of a clinical trial. We also assessed efficacy of retreatment with anti-PD-1 therapy with or without ipilimumab in relapsing patients.